This is an open-label study, to evaluated epitinib, which is a selective epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR TKI), to treat glioblastoma patients with
EGFR gene amplification. As epitinib could cross blood-brain barrier (BBB), inhibition of
EGFR may provide a novel mechanism in treating glioblastoma.